Overview

Regorafenib and Nivolumab Simultaneous Combination Therapy

Status:
Completed
Trial end date:
2020-11-26
Target enrollment:
Participant gender:
Summary
the efficacy and safety ofhe use of regorafenib in combination with nivolumab
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Kohei Shitara
Collaborators:
Bayer Yakuhin, Ltd.
Ono Pharmaceutical Co. Ltd
Treatments:
Antibodies, Monoclonal
Nivolumab